Knoll Capital Management LP recently announced the acquisition of new stake in Applied Therapeutics Inc (NASDAQ:APLT). The institutional investor has increased its shareholding in the Healthcare company by 49.63% to 5.16 million shares with purchase of 1.71 million shares. This fresh investment now brings its stake to 6.68% valued currently at $10.89 million. In addition, Propel Bio Management LLC raised its holdings by 4.76 million to 4.76 million shares.
With over 6.01 million Applied Therapeutics Inc (APLT) shares trading Monday and a closing price of $2.26 on the day, the dollar volume was approximately $13.57 million. The shares have shown a positive half year performance of 62.59% and its price on 01/08/24 gained nearly 0.44%. Currently, there are 77.23M common shares owned by the public and among those 54.45M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 4,526,737 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 2,337,702 shares.
The top 3 mutual fund holders in Applied Therapeutics Inc are FTIF SICAV – Biotechnology Discov, Franklin Biotechnology Discovery, and Fidelity Select Port. – Biotechno. FTIF SICAV – Biotechnology Discov owns 10.37 million shares of the company’s stock, all valued at over $21.89 million. The company sold 46700.0 shares recently to bring their total holdings to about 13.43% of the shares outstanding. Franklin Biotechnology Discovery sold 29615.0 shares to see its total holdings shrink to 5.0 million shares valued at over $10.54 million and representing 6.47% of the shares outstanding. Fidelity Select Port. – Biotechno sold -0.21 million shares to bring its total holdings to over 2.43 million shares at a value of $5.12 million. Fidelity Select Port. – Biotechno now owns shares totaling to 3.14% of the shares outstanding.
Shares of Applied Therapeutics Inc (NASDAQ: APLT) opened at $2.17, down -$0.08 from a prior closing price of $2.25. However, the script later moved the day high at 2.3600, up 0.44%. The company’s stock has a 5-day price change of -32.54% and 1.57% over the past three months. APLT shares are trading -32.54% year to date (YTD), with the 12-month market performance up to 152.85% higher. It has a 12-month low price of $0.76 and touched a high of $4.42 over the same period. APLT has an average intraday trading volume of 1.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.78%, -12.01%, and 24.58% respectively.
Institutional ownership of Applied Therapeutics Inc (NASDAQ: APLT) shares accounts for 59.66% of the company’s 77.23M shares outstanding. Mutual fund holders own 28.93%, while other institutional holders and individual stakeholders account for 30.74% and 21.36% respectively.
It has a market capitalization of $174.54M and a beta (3y monthly) value of 1.59. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 23.60% over the week and 14.79% over the month.
Analysts forecast that Applied Therapeutics Inc (APLT) will achieve an EPS of -$0.27 for the current quarter, -$0.23 for the next quarter and -$0.98 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.34 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 28.98%, and 43.89% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Applied Therapeutics Inc (APLT) as a “Strong Buy” at a consensus score of 1.50. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the APLT, a number of firms have released research notes about the stock. Barclays stated their Equal Weight rating for the stock in a research note on January 04, 2022, with the firm’s price target at $44-$7.
